Greenwood Capital Associates LLC Has $401,000 Holdings in CONMED Co. (NYSE:CNMD)

Greenwood Capital Associates LLC decreased its holdings in shares of CONMED Co. (NYSE:CNMD) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,862 shares of the company’s stock after selling 161 shares during the quarter. Greenwood Capital Associates LLC’s holdings in CONMED were worth $401,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Nordea Investment Management AB raised its holdings in CONMED by 31.5% in the 4th quarter. Nordea Investment Management AB now owns 73,587 shares of the company’s stock worth $5,141,000 after acquiring an additional 17,633 shares during the period. Avity Investment Management Inc. bought a new position in CONMED during the fourth quarter worth about $278,000. Intech Investment Management LLC boosted its stake in CONMED by 177.6% in the 3rd quarter. Intech Investment Management LLC now owns 15,922 shares of the company’s stock valued at $1,145,000 after buying an additional 10,187 shares in the last quarter. Millrace Asset Group Inc. acquired a new stake in shares of CONMED in the 3rd quarter valued at $1,665,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in CONMED by 1.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 67,062 shares of the company’s stock valued at $4,823,000 after buying an additional 1,095 shares in the last quarter.

CONMED Price Performance

NYSE:CNMD opened at $72.98 on Wednesday. The company has a market cap of $2.25 billion, a P/E ratio of 17.33, a P/E/G ratio of 1.04 and a beta of 1.46. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.27 and a quick ratio of 1.06. The firm’s fifty day moving average price is $70.62 and its two-hundred day moving average price is $70.19. CONMED Co. has a one year low of $61.05 and a one year high of $88.60.

CONMED Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 3rd. Shareholders of record on Friday, December 20th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date was Friday, December 20th. CONMED’s dividend payout ratio is currently 19.00%.

Analyst Upgrades and Downgrades

A number of research firms have commented on CNMD. StockNews.com lowered CONMED from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $97.00 target price on shares of CONMED in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $79.80.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.